A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 2000
- Registration Number
- NCT06043700
- Locations
- ๐บ๐ธ
Eisai Site #3, Clermont, Florida, United States
๐บ๐ธEisai Site #1, Lady Lake, Florida, United States
๐บ๐ธEisai Site #2, District Heights, Maryland, United States
A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 15
- Registration Number
- NCT05607537
- Locations
- ๐ฌ๐ง
Labcorp Clinical Research Unit, Leeds, United Kingdom
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT04840927
- Locations
- ๐ฌ๐ง
Quotient Sciences, Nottingham, United Kingdom
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04493255
- Locations
- ๐ฌ๐ง
Covance Clinical Research Unit, Leeds, United Kingdom
A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 243
- Registration Number
- NCT04257604
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 191
- Registration Number
- NCT04252846
- Locations
- ๐ฎ๐น
Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy
๐ท๐บKrasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy, Krasnoyarsk, Russian Federation
๐ท๐บCity Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation
To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 14
- Registration Number
- NCT03002493
- Locations
- ๐ณ๐ฑ
Netherlands Cancer Institute, Amsterdam, Netherlands
๐ณ๐ฑUniversity Medical Center Utrecht, Utrecht, Netherlands
Extended Treatment in Metastatic Breast Cancer With Eribulin
Completed
- Conditions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 45
- Registration Number
- NCT02769364
Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 42
- Registration Number
- NCT02533102
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
Completed
- Conditions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 77
- Registration Number
- NCT02443428
ยฉ Copyright 2024. All Rights Reserved by MedPath